Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2013

01-05-2013

The immunology of Leishmania/HIV co-infection

Authors: Ifeoma Okwor, Jude Eze Uzonna

Published in: Immunologic Research | Issue 1/2013

Login to get access

Abstract

Leishmaniases are emerging as an important disease in human immunodeficiency virus (HIV)–infected persons living in several sub-tropical and tropical regions around the world, including the Mediterranean. The HIV/AIDS pandemic is spreading at an alarming rate in Africa and the Indian subcontinent, areas with very high prevalence of leishmaniases. The spread of HIV into rural areas and the concomitant spread of leishmaniases to suburban/urban areas have helped maintain the occurrence of Leishmania/HIV co-infection in many parts of the world. The number of cases of Leishmania/HIV co-infection is expected to rise owing to the overlapping geographical distribution of the two infections. In Southwestern Europe, there is also an increasing incidence of Leishmania/HIV co-infection (particularly visceral leishmaniasis) in such countries as France, Italy, Spain and Portugal. Studies suggest that in humans, very complex mechanisms involving dysregulation of host immune responses contribute to Leishmania-mediated immune activation and pathogenesis of HIV. In addition, both HIV-1 and Leishmania infect and multiply within cells of myeloid or lymphoid origin, thereby presenting a perfect recipe for reciprocal modulation of Leishmania and HIV-1-related disease pathogenesis. Importantly, because recovery from leishmaniases is associated with long-term persistence of parasites at the primary infection sites and their draining lymph nodes, there is very real possibility that HIV-mediated immunosuppression (due to CD4+ T cell depletion) could lead to reactivation of latent infections (reactivation leishmaniasis) in immunocompromised patients. Here, we present an overview of the immunopathogenesis of Leishmania/HIV co-infection and the implications of this interaction on Leishmania and HIV disease outcome.
Literature
1.
Alvar J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.PubMedCrossRef
2.
Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000;2(14):1765–73.PubMedCrossRef
3.
Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol. 2003;97(Suppl 1):29–45.PubMedCrossRef
4.
Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev. 2011;240(1):286–96.PubMedCrossRef
5.
Melby PC. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol. 2002;3(8):557–70.PubMedCrossRef
6.
Scott P, et al. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev. 2004;201:318–38.PubMedCrossRef
7.
8.
9.
Dougan S, et al. HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance. Epidemiol Infect. 2008;136(2):145–56.PubMedCrossRef
10.
Centre for Disease Control. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men- New York City and California. Morb Mortal Wkly Rep. 1981;3.
11.
Hymes KB, et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2(8247):598–600.PubMedCrossRef
12.
Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007;37(Suppl 1):S94–102.PubMedCrossRef
13.
UNAIDS. Global report: UNAIDS Report on Global AIDS Epidemic. 2012.
14.
Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol. 2006;303:97–120.PubMedCrossRef
15.
Greene WC, Peterlin BM. Charting HIV’s remarkable voyage through the cell: basic science as a passport to future therapy. Nat Med. 2002;8(7):673–80.PubMedCrossRef
16.
Schroder AR, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521–9.PubMedCrossRef
17.
Garrus JE, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107(1):55–65.PubMedCrossRef
18.
Cruz I, et al. Leishmania/HIV co-infections in the second decade. Indian J Med Res. 2006;123(3):357–88.PubMed
19.
Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3–15.PubMedCrossRef
20.
Sinha PK, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 2011;53(7):e91–8.PubMedCrossRef
21.
Diro A, Hailu A, Lynen L. VL-HIV co-infection in East-Africa: current challenges and perspectives. In: 7th European congress on tropical medicine and international health. Barcelona, Spain; 2011.
22.
Chicharro C, Alvar J. Lower trypanosomatids in HIV/AIDS patients. Ann Trop Med Parasitol. 2003;97(Suppl 1):75–8.PubMedCrossRef
23.
WHO. Leishmania/HIV co-infection in south-western Europe 1990–1998: a retrospective analysis f 965 cases. Geneva: World Health Orginization; 2000. p. 14.
24.
Alvar J, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298–319.PubMed
25.
Alvar J, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59. table of contents.PubMedCrossRef
26.
Alvar J, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol. 1996;14(5):541–6.PubMedCrossRef
27.
Hotez PJ, et al. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis. 2004;38(6):871–8.PubMedCrossRef
28.
Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res. 2006;123(3):275–88.PubMed
29.
Joshi DD, Sharma M, Bhandari S. Visceral leishmaniasis in Nepal during 1980–2006. J Commun Dis. 2006;38(2):139–48.PubMed
30.
Schenkel K, et al. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health. 2006;11(12):1792–9.PubMedCrossRef
31.
Singh SP, et al. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health. 2006;11(6):899–905.PubMedCrossRef
32.
UNAIDS. Global Report: UNAIDS Report on Global AIDS Epidemic. 2010.
33.
UNAIDS. Global Report: UNIADS Report on Global AIDS Epidemic. 2009.
34.
Singh S, et al. A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India. J Commun Dis. 1999;31(2):73–7.PubMed
35.
Gurubacharya RL, et al. Prevalence of visceral leishmania and HIV co-infection in Nepal. Indian J Med Res. 2006;123(3):473–5.PubMed
36.
Guiguemde RT, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg. 2003;97(2):168–9.PubMedCrossRef
37.
Couppie P, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol. 2004;151(6):1165–71.PubMedCrossRef
38.
Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health. 2003;8(8):733–9.PubMedCrossRef
39.
UNAIDS/WHO. UNAIDS/WHO AIDS Epidemic Updates. 2005.
40.
Ngouateu OB, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg. 2012;106(3):137–42.PubMedCrossRef
41.
WHO. Report of the fifth consultative meeting on Leishmania/HIV coinfection, 2007: Addis Ababa, Ethiopia.
42.
Daher EF, et al. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol. 2009;95(3):652–5.PubMedCrossRef
43.
Nascimento ET, et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg. 2011;105(5):298–300.PubMedCrossRef
44.
Orsini M, et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2012;106(5):283–8.PubMedCrossRef
45.
Lindoso JAL. Visceral Leishmaniasis—HIV co-infection: emerging in South America. In: 7th European congress on tropical medicine and international health. Barcelona, Spain: Wiley Blackwell; 2011.
46.
Bernier R, et al. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol. 1995;69(11):7282–5.PubMed
47.
Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8(3):72–5.PubMed
48.
Santos-Oliveira JR, et al. High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis. 2010;10:358.PubMedCrossRef
49.
50.
51.
Garg R, Trudel N, Tremblay MJ. Consequences of the natural propensity of Leishmania and HIV-1 to target dendritic cells. Trends Parasitol. 2007;23(7):317–24.PubMedCrossRef
52.
Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem. 2002;9(21):1893–903.PubMedCrossRef
53.
Azzam R, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses. 2006;22(7):619–29.PubMedCrossRef
54.
Kedzierska K, et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol. 2003;26(2):247–63.PubMedCrossRef
55.
Barreto-de-Souza V, et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis. 2006;194(6):846–54.PubMedCrossRef
56.
Turco SJ. Adversarial relationship between the leishmania lipophosphoglycan and protein kinase C of host macrophages. Parasite Immunol. 1999;21(12):597–600.PubMedCrossRef
57.
Garg R, et al. Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. PLoS Negl Trop Dis. 2009;3(5):e441.PubMedCrossRef
58.
Wolday D, et al. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun. 1999;67(10):5258–64.PubMed
59.
Griffin GE, et al. Induction of NF-kappa B during monocyte differentiation is associated with activation of HIV-gene expression. Res Virol. 1991;142(2–3):233–8.PubMedCrossRef
60.
Bernier R, et al. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol. 1998;160(6):2881–8.PubMed
61.
Wolday D, et al. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis. 1998;30(1):29–34.PubMedCrossRef
62.
Zhao C, et al. In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol. 2006;87(Pt 5):1295–302.PubMedCrossRef
63.
Lopez-Velez R, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58(4):436–43.PubMed
64.
Bossolasco S, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003;41(11):5080–4.PubMedCrossRef
65.
Lindoso JA, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. 2009;160(2):311–8.PubMedCrossRef
66.
Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378–84.PubMedCrossRef
67.
Owens BM, et al. IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c(+) cell populations during visceral leishmaniasis. PLoS Pathog. 2012;8(7):e1002827.PubMedCrossRef
68.
Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol. 1995;13:151–77.PubMedCrossRef
69.
Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 1993;61(7):2952–9.PubMed
70.
Scott P, et al. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev. 1989;112:161–82.PubMedCrossRef
71.
Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol. 1989;68(3):369–72.PubMedCrossRef
72.
Scharton-Kersten T, et al. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995;154(10):5320–30.PubMed
73.
Himmelrich H, et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol. 2000;164(9):4819–25.PubMed
74.
Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol. 2007;51(2):229–42.PubMedCrossRef
75.
Wolday D, et al. HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol. 1994;39(4):380–6.PubMedCrossRef
76.
77.
Wolday D, et al. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS. 2000;14(8):921–9.PubMedCrossRef
78.
Nigro L, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Am J Trop Med Hyg. 1999;60(1):142–5.PubMed
79.
Milano S, et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol. 2002;127(2):360–5.PubMedCrossRef
80.
d’Ettorre G, et al. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop. 2006;99(1):83–7.PubMedCrossRef
81.
Olivier M, et al. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol. 2003;97(Suppl 1):79–98.PubMedCrossRef
82.
Medrano FJ, et al. Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol. 1998;114(3):403–7.PubMedCrossRef
83.
Villanueva JL, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2000;19(10):798–801.PubMedCrossRef
84.
Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol. 2003;97(Suppl 1):143–7.PubMedCrossRef
85.
Rosenthal E, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1184–5.PubMedCrossRef
86.
Tortajada C, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(3):364–6.PubMed
87.
Tumbarello M, et al. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS. 2000;14(18):2948–9.PubMedCrossRef
88.
ter Horst R, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46(11):1702–9.PubMedCrossRef
89.
de Gaetano Donati K, et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents. 2000;16(3):357–60.PubMedCrossRef
90.
de Gaetano Donati K, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-infected subjects. J Chemother. 2003;15(1):60–5.PubMed
91.
Albrecht H, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12(10):1149–54.PubMedCrossRef
92.
Durand I, et al. Disseminated cutaneous leishmaniasis revealing human immunodeficiency virus infection. Ann Dermatol Venereol. 1998;125(4):268–70.PubMed
93.
Rueda CM, et al. HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS ONE. 2012;7(1):e30307.PubMedCrossRef
94.
Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220–6.PubMed
95.
Aebischer T. Recurrent cutaneous leishmaniasis: a role for persistent parasites? Parasitol Today. 1994;10(1):25–8.PubMedCrossRef
96.
Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 2004;20(11):524–30.PubMedCrossRef
97.
Berhe N, et al. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg. 1995;89(2):205–7.PubMedCrossRef
98.
Berhe N, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS. 1999;13(14):1921–5.PubMedCrossRef
99.
Wolday D, et al. Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol. 2001;190(1–2):65–7.PubMed
100.
Saravia NG, et al. Recurrent lesions in human Leishmania braziliensis infection–reactivation or reinfection? Lancet. 1990;336(8712):398–402.PubMedCrossRef
101.
Stenger S, et al. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med. 1996;183(4):1501–14.PubMedCrossRef
102.
Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol. 2000;165(2):896–902.PubMed
103.
Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Neg Trop Dis. 2011;5(6):e1153.CrossRef
104.
Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220–6.PubMed
105.
Belkaid Y, et al. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7.PubMedCrossRef
106.
Uzonna JE, et al. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001;167(12):6967–74.PubMed
107.
Klatt NR, et al. SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood. 2011;118(22):5803–12.PubMedCrossRef
Metadata
Title
The immunology of Leishmania/HIV co-infection
Authors
Ifeoma Okwor
Jude Eze Uzonna
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Immunologic Research / Issue 1/2013
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8389-8

Other articles of this Issue 1/2013

Immunologic Research 1/2013 Go to the issue

OriginalPaper

Limited replication of influenza A virus in human mast cells

OriginalPaper

Adjuvant dependence of APS pathology-related low-affinity antibodies during secondary immune response to tetanus toxoid in BALB/c mice

OriginalPaper

Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts

OriginalPaper

For many but not for all: how the conformational flexibility of the peptide/MHCII complex shapes epitope selection

OriginalPaper

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer

OriginalPaper

Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity